Mantle Cell Lymphoma
Conditions
Brief summary
2-years progression-free survival (PFS) of the HR patients from date of enrollment
Detailed description
The proportion of molecular response (analyzed in the labs of the FIL-MRD Network), The progression-free survival (PFS) of all enrolled patients, and of different subgroups (i.e TP53 mutated patients), The overall survival (OS), The duration of responses (DoR), The proportion of complete remission (CR) before and after venetoclax in the HR group and/or in the LR not responding to R-BAC., The proportion of patients that complete the expected treatment schedule, The safety of venetoclax when administered as consolidation or maintenance after R-BAC
Interventions
DRUGBENDAMUSTINE
DRUGCYTARABINE
DRUGVENETOCLAX
DRUGRITUXIMAB
Sponsors
Fondazione Italiana Linfomi Ets
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-years progression-free survival (PFS) of the HR patients from date of enrollment | — |
Secondary
| Measure | Time frame |
|---|---|
| The proportion of molecular response (analyzed in the labs of the FIL-MRD Network), The progression-free survival (PFS) of all enrolled patients, and of different subgroups (i.e TP53 mutated patients), The overall survival (OS), The duration of responses (DoR), The proportion of complete remission (CR) before and after venetoclax in the HR group and/or in the LR not responding to R-BAC., The proportion of patients that complete the expected treatment schedule, The safety of venetoclax when administered as consolidation or maintenance after R-BAC | — |
Countries
Italy
Outcome results
None listed